益盛药业(002566) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥218,657,311.81, representing a year-on-year increase of 0.71%[4] - The net profit attributable to shareholders for Q3 2021 was ¥23,880,406.66, an increase of 11.88% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥23,991,300.85, up 56.76% year-on-year[4] - Total operating revenue for Q3 2021 reached CNY 673,541,386.30, an increase of 9.7% compared to CNY 614,016,426.03 in the same period last year[20] - Operating profit for the period was CNY 88,409,326.92, up from CNY 77,844,776.38, reflecting a growth of 13.4% year-over-year[22] - Net profit attributable to the parent company was CNY 65,251,454.52, representing a 20.4% increase from CNY 54,188,768.07 in the previous year[22] - The company reported a basic earnings per share of CNY 0.1972, compared to CNY 0.1637 in the same quarter last year, marking a 20.4% increase[23] - The basic earnings per share for Q3 2021 was ¥0.0722, an increase of 11.94% compared to the same period last year[4] Cash Flow - The cash flow from operating activities for the year-to-date period reached ¥163,004,140.39, reflecting a significant increase of 101.25%[4] - The net cash flow from operating activities for Q3 2021 was ¥163,004,140.39, a significant increase of 101.01% compared to ¥80,995,109.69 in Q3 2020[26] - Cash inflow from operating activities totaled CNY 823,066,466.86, an increase from CNY 698,939,437.12 in the previous year, indicating a growth of 17.8%[24] - Cash outflows related to operating activities totaled ¥660,062,326.47, an increase of 6.73% from ¥617,944,327.43 in Q3 2020[26] - The net cash flow from investing activities was -¥100,684,903.68, a decline from -¥5,049,230.35 in the same period last year, indicating increased investment outflows[26] - Cash inflows from financing activities totaled ¥397,450,000.00, while cash outflows were ¥463,348,484.84, resulting in a net cash flow of -¥65,898,484.84 for Q3 2021[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,782,434,606.37, a decrease of 0.49% from the end of the previous year[4] - The company's total current assets as of September 30, 2021, amount to ¥2,166,911,877.68, a decrease from ¥2,223,356,178.91 at the end of 2020[18] - The total assets of the company as of September 30, 2021, are ¥2,782,434,606.37, slightly down from ¥2,796,099,005.75 at the end of 2020[18] - Total liabilities amounted to CNY 614,470,617.15, a decrease from CNY 663,864,893.91 at the end of the previous period[20] - Total liabilities stood at ¥663,864,893.91, remaining consistent with the previous year, which suggests effective liability management[31] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,677[12] - Zhang Yisheng holds 39.08% of shares, totaling 129,348,530 shares, with 97,011,397 shares under lock-up conditions[12] - The company's equity attributable to shareholders increased by 2.77% to ¥2,051,040,844.15 compared to the end of the previous year[4] - The company's equity attributable to shareholders was ¥1,995,717,937.63, reflecting stability in shareholder value compared to the previous year[31] Investment and Development - The company reported a significant increase of 246.56% in construction in progress, amounting to ¥93,827,462.31, due to increased investment in the cosmetics deep processing industry project[9] - Research and development expenses for the quarter were CNY 14,891,356.12, slightly up from CNY 14,423,381.56, indicating continued investment in innovation[20] - The company has ongoing discussions regarding potential market expansion and new product development strategies[13] Financial Management - Financial expenses decreased by 41.90% to ¥4,482,915.62, primarily due to increased interest from agreement deposits[9] - The company has adopted new leasing standards starting in 2021, which may impact future financial reporting and asset management strategies[28] - The third quarter report for 2021 was not audited, which may affect the reliability of the financial data presented[32] Inventory and Receivables - The company's inventory as of September 30, 2021, is ¥1,609,706,267.63, compared to ¥1,615,762,224.99 at the end of 2020[18] - The company reported accounts receivable of ¥207,843,199.78 as of September 30, 2021, up from ¥205,229,958.10 at the end of 2020[18]